Member Directory

All Partners have extensive experience, including senior executive positions in large pharmaceutical and entrepreneurial biotechnology companies. Their collective experience extends across business development and licensing, drug discovery and development, marketing, intellectual property management, venture capital and investment banking.. . Our client list ranges from small European start-ups through established US biotechs to large Japanese pharmaceutical companies. Kagulex Consulting provides a range of business and product development services including:. . -Global Product and Patent Licensing and Corporate Partnering. -Intellectual Property Strategy and Management. -Merger and Acquisition Advice and Due Diligence. -Pre-clinical Planning and Implementation. -Clinical and Regulatory Strategy Development and Implementation. -Strategic Business Plan Development. -Product and Technology Assessment. -Venture Facilitation

KELYON was founded in 2008 by a group of young and dynamic ICT and healthcare professionals who decided to put their knowledge and competencies together with the aim of improving the lives of patients and helping shape the future of healthcare around the world.. Due to our international experience in the healthcare sector, Kelyon stands as a certified and highly reliable supplier in the booming digital healthcare market, specialized in Software Medical Devices and with specific understanding and awareness of the increasing need for strict compliance to privacy and safety regulations regarding patient data. . Kelyon provides comprehensive and complete expertise in developing Software Medical Devices and eHealth applications for the prevention, diagnosis, and treatment of complex diseases, and offers complete and systematic guidance for SMD and e-Health app needs, covering all phases of the process, from concept development to final roll-out and maintenance, while complying to all regulatory requirements.

As the leading kidney research charity in the UK, nothing is going to stop us in our urgent mission to end kidney disease. We’re here to be heard, to make a difference, to change the future. This is a disease that ruins and destroys lives. It must be stopped.

Over the past 60 years, our research has made an impact. But kidney failure is rising, as are the factors contributing to it, such as diabetes and obesity.

Today, we are more essential than ever.

Kidney disease affects three million people in the UK, treatments can be gruelling and currently there is no cure. Only research will end this and nobody can do it but us, by offering kidney patients and their families hope for the future. We’re taking it on. But we can’t do it without you.

King's Business is responsible for driving innovation at King's College London. Through the development of new opportunities and partnerships we optimise the impact of research and create value for the College in its externally-facing activities. This includes securing partnerships with business and other sectors through diverse mechanisms such as patenting and licensing, the creation of spin-out companies, collaborative and contract research, consultancy and staff secondments to and from industry.

KISS - the multiplier agency.

An award-winning B2B marketing agency where expertise meets an unwavering desire for exceptional results. If you’re ambitious about multiplying the impact of your marketing performance, we are the agency to help your grow your business.

Fuelled by a team of experts across strategy, creativity, technology and performance, we will amplify your marketing performance and grow your business through our theory of multiplication: Creativity x Technology x Data.

We harness the power of creativity to ensure you stand out in the marketplace, enabling this with the latest technology. Everything we do is informed by data to deliver your message through the right channels, to the right audiences, at the right time to deliver maximum impact.

From concept to completion, our projects multiply results.
Growth is good. Multiplying is better.